Induction Optimization with Stelara for Crohn s Disease

Go Back to All Clinical Trials

Induction Optimization with Stelara for Crohn s Disease

Brief description of study

The purpose of this study is to compare the effectiveness of a second weight based dose of Stelara given intravenously to the standard dose administered subcutaneously at 8 weeks. In this study, the second weight-based intravenous induction dose of Stelara is considered investigational because it is outside of the FDA-approved dosing or “off-label”.

Clinical Study Identifier: s19-01401

ClinicalTrials.gov Identifier: NCT04629196

Principal Investigators: David P Hudesman, iConnect Langone.

Other Investigators: Adam Faye, Ariela Holmer, Simon J Hong, Jordan E Axelrad, Shannon Chang.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies